Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Slides:

Advertisements

Similar presentations

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Advertisements

M. Inghammar, G. Engström, G. Kahlmeter, B. Ljungberg, C. -G

Pathological changes in chronic obstructive pulmonary disease

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Nat. Rev. Cardiol. doi: /nrcardio

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Diagnostic and management strategy recommended in obstructive sleep apnoea syndrome (OSAS) suspicion [52, 75–77]. Diagnostic and management strategy recommended.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

Conceptual framework of the interaction between environmental exposure including smoking, alpha-1 antitrypsin (AAT) level and/or AAT genotype, other genetic.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.

A white elephant or the elephant in the room

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Occurrence of morning symptoms

Representative photomicrograph of small airways abnormalities in a subject with chronic obstructive pulmonary disease. Representative photomicrograph of.

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

The distribution of the extent of change in inspiratory capacity (IC) during exercise is shown in moderate-to-severe chronic obstructive pulmonary disease.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Prevalence of comorbidities in pooled studies of patients with chronic obstructive pulmonary disease (COPD). Prevalence of comorbidities in pooled studies.

A–f) Respiratory mechanical measurements during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease (COPD) and age-matched.

a) Mortality per time point (p<0

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Effects of chronic obstructive pulmonary disease (COPD) severity on different parameters of ventilatory inefficiency during incremental cardiopulmonary.

Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Kaplan–Meier survival curves for outcomes among chronic obstructive pulmonary disease (COPD) patients without obstructive sleep apnoea (OSA) (COPD group),

Oxidative stress in exacerbations of chronic obstructive pulmonary disease (COPD). a) Superoxide (O2·) anion release from peripheral blood neutrophils.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Incidence of chronic obstructive pulmonary disease according to the history of chronic cough/phlegm. Incidence of chronic obstructive pulmonary disease.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Exercise confers cardioprotection through improved vascular function.

A) Levels of nitrosothiols in breath condensate in normal healthy smokers and patients with chronic obstructive pulmonary disease (COPD). b) Increased.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

A) 8-isoprostane levels in exhaled breath condensate in smokers with chronic obstructive pulmonary disease (COPD). *: p

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

Pathophysiological interactions between chronic obstructive pulmonary disease (COPD), sleep and obstructive sleep apnoea syndrome (OSAS). Pathophysiological.

The relationship between triggers, pathological changes, disease characteristics, symptoms and quality of life (QoL) in chronic obstructive pulmonary disease.

Comorbidities/associated conditions/complications assessed in patients diagnosed with idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research.

Increase of physical activity over time associated with lower HF risk

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

A) Mucus replete left lower lobe bronchiectasis in a young X-linked agammaglobulinaemia patient (coronal and axial view). b) Pathogenesis of bronchiectasis.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Evidence-based indications for noninvasive positive-pressure ventilation (NPPV) according to the severity and time of acute respiratory failure (ARF) [18].

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Schematic of the relationship between smoking and legume consumption (smoking–diet relationship) in relation to pulmonary inflammation, systemic inflammation,

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

Frequency distribution histograms of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) total, the COPD Assessment Test (CAT), the St George’s.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. CVS: cardiovascular; COPD: chronic obstructive pulmonary disease. Data are presented as odds ratio (95% confidence interval), except hospital cohort which is presented as relative risk (95% confidence interval) and following COPD exacerbation which is presented as hazard ratio (95% confidence interval). R. P. Young et al. Eur Respir Rev 2009;18:222-232 ©2009 by European Respiratory Society